Literature DB >> 3943762

Stage IIIA carcinoma of the uterine cervix.

J G Cardinale, R E Peschel, E Gutierrez, D S Kapp, E I Kohorn, P E Schwartz.   

Abstract

Carcinoma of the uterine cervix presenting with extension to the lower third of the vagina but without hydronephrosis or fixation to the pelvic sidewall is uncommon. It is classified as stage IIIA by the criteria of the International Federation of Gynecology and Obstetrics (FIGO) and accounts for less than 2% of all cervical cancer cases seen in our institution. Because of the paucity of such cases, the results of treatment of FIGO stage IIIA cervical cancer are generally not reported separately. The radiation therapy treatment program at Yale--New Haven Hospital for stage IIIA patients includes intracavitary and vaginal brachytherapy plus external beam radiation therapy, with a strong emphasis on individualization of treatment. The results of treatment in 17 stage IIIA patients were reviewed. Local--regional tumor control was achieved in 12 of the 17 patients (71%) treated. The actuarial 5-year disease-free survival rate was 58%. Our results suggest that FIGO stage IIIA carcinoma of the cervix has a much better prognosis than FIGO stage IIIB cervical cancer, and we recommend that the results of treatment for FIGO stage IIIA be reported separately.

Entities:  

Mesh:

Year:  1986        PMID: 3943762     DOI: 10.1016/0090-8258(86)90224-6

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

1.  Modified Fletcher's 3-channel brachytherapy system with vaginal line source loading versus uterine tandem and vaginal cylinder system in Stage IIIA cervical cancer.

Authors:  Jsh Low; Kb Ng
Journal:  Biomed Imaging Interv J       Date:  2006-01-01

2.  Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion.

Authors:  Kanyarat Katanyoo
Journal:  J Gynecol Oncol       Date:  2017-11       Impact factor: 4.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.